Video
Author(s):
Drs Raj Chovatiya and Neal Bhatia highlight the biological targets of current and emerging treatments for the management of atopic dermatitis and discuss the importance of safety and long-term data.
Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Tralokinumab Shows Long-Term Efficacy for AD in Sensitive Areas
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Significant Proportion of Patients With AD Maintain Stable EASI With Tralokinumab Treatment
9 Months of Treatment With Tralokinumab Results in Improved QoL, Itch, and Sleep